Last updated on June 2020

A Study to Evaluate ALN-AGT01 in Patients With Hypertension


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 in participants with hypertension. The study will be conducted in 5 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part C will be a multiple dose (MD) phase in hypertensive participants, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.

Clinical Study Identifier: NCT03934307

Find a site near you

Start Over

Clinical Trial Site

Belfast, United Kingdom
  Connect »

Clinical Trial Site

London, United Kingdom
  Connect »

Clinical Trial Site

Manchester, United Kingdom
  Connect »